Drug Profile
MEDI 6570
Alternative Names: MEDI-6570; MEI-6570Latest Information Update: 04 Dec 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Antihyperlipidaemics; Cardiovascular therapies
- Mechanism of Action Oxidised low density lipoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atherosclerosis; Coronary disorders
Most Recent Events
- 08 Nov 2023 AstraZeneca completes a phase-II clinical trials in Coronary disorders in USA, Hungary, Poland, Czech Republic, Australia, Canada, Italy, Japan, Netherland, Spain and United Kingdom(SC) (NCT04610892)
- 15 Jun 2023 National Heart Centre Singapore plans a phase II trial in Type 2 diabetes mellitus and Vascular disorders in Singapore (SC, Injection) (NCT05912218)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Atherosclerosis in USA (SC, Injection)